- Sofinnova closes its second crossover fund at €725 million.
- The fund will back around 15 clinical-stage life sciences companies.
- Focus areas include European biopharma and medtech, with selective global investments.
European life sciences companies are moving from clinical validation to commercialisation, and the funds backing them are growing. However, scaling a promising therapy or medical technology requires substantial capital, particularly when companies enter expensive clinical trials and prepare for international markets.
Sofinnova Partners, the Paris-based life sciences venture capital firm, announced on November 16 that it had closed its second crossover fund at €725 million, exceeding its original target. Crossover funds typically back late-stage private companies ahead of a listing or sale.
Sofinnova Crossover II will invest in approximately 15 companies, primarily across Europe, with selective investments in the US and other international markets. The strategy focuses on late-stage biopharma and medtech businesses that need capital to advance clinical programmes, expand globally and prepare for commercial launch.
Building on more than 50 years of investing
Founded in 1972, Sofinnova Partners has backed more than 500 companies and manages over €4 billion in assets. The firm operates from Paris, London and Milan, investing across the life sciences sector from seed-stage ventures to later-stage businesses.
The new fund builds on the firm’s first crossover vehicle. Sofinnova says Crossover I backed LimFlow, acquired by Inari Medical; Calliditas Therapeutics, acquired by Asahi Kasei; Amolyt Pharma, acquired by AstraZeneca; and Abivax, which listed on Nasdaq. The firm says these outcomes show it can help late-stage companies get from clinical development to global scale.
“The scale of this fund reflects both the maturity of the European life sciences ecosystem and the rising demand for capital that can help companies to reach global markets. Europe is producing a growing number of world-class life sciences companies, and we believe they should have access to investors that can support them through the critical stages of growth and commercialisation,” said Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners.
Backing the next generation of clinical-stage companies
Sofinnova Crossover II has already invested in three companies: Hemab Therapeutics, CellCentric and Neurent Medical.
The fund’s strategy is led by partners Joe Anderson, Kinam Hong, Cedric Moreau, Jacques Theurillat and David Evans. It is backed by the European Tech Champions Initiative (ETCI), a fund of funds managed by the European Investment Fund.
“We continue to see exceptional opportunities emerging across European life sciences. Many companies now have scientific strength, clinical validation, and leadership teams needed to compete on a global stage. With Sofinnova Crossover II, we are well positioned to support that next generation of leaders while maintaining the disciplined investment approach that defined our first fund,” said Hong, partner at Sofinnova Partners.
The close follows a run of fundraises across Sofinnova’s strategies. In November 2025, the firm closed Sofinnova Capital XI at €650 million, targeting biopharmaceutical and medical technology companies. Earlier, its Biovelocita II fund raised €165 million to accelerate biotech company creation across Europe. In September 2026, it closed the €82 million MD Start IV fund to build six to eight medtech companies from the ground up.
Closing Europe’s late-stage funding gap
Sofinnova is competing with specialist investors raising ever larger funds for clinical-stage biotech. Paris-based Jeito Capital announced the close of its second fund at €1 billion in April, to back clinical-stage biopharma companies. Netherlands-based Forbion raised €2.3 billion across two funds for about 30 biotech companies in Europe and North America. Kurma Partners closed its Biofund IV at €215 million.
Europe still struggles to fund companies through the expensive late stage. According to PitchBook, the region accounts for 20.5% of global biotech funding this year, its highest share since 2018, yet US biotech startups raise three times as much. Sofinnova is one of the European investors, alongside Novo Holdings, that launched the European Life Sciences Coalition this year to call for more public and private capital.
Crossover II puts about 15 large cheques behind that argument. The open question is whether Europe’s best clinical-stage companies will now stay and scale at home, or keep heading to US investors and exchanges for the money to finish the job.